BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16:269-278. [PMID: 20028762 DOI: 10.1158/1078-0432.ccr-09-2439] [Cited by in Crossref: 183] [Cited by in F6Publishing: 65] [Article Influence: 14.1] [Reference Citation Analysis]
Number Citing Articles
1 Clément-Duchêne C, Godbert B, Martinet Y. [Anti-angiogenic agents in the treatment of lung cancer: indications and toxicities]. Rev Mal Respir 2012;29:161-77. [PMID: 22405111 DOI: 10.1016/j.rmr.2011.06.017] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Buttigliero C, Bertaglia V, Novello S. Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. Transl Lung Cancer Res 2016;5:610-27. [PMID: 28149756 DOI: 10.21037/tlcr.2016.09.03] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
3 Cedrych I, Kruczała MA, Walasek T, Jakubowicz J, Blecharz P, Reinfuss M. Systemic treatment of non-small cell lung cancer brain metastases. Contemp Oncol (Pozn) 2016;20:352-7. [PMID: 28373815 DOI: 10.5114/wo.2016.64593] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
4 Gadgeel SM, Cote ML, Schwartz AG, Matherly LH, Wozniak A, Bepler G. Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resist Updat 2010;13:196-204. [PMID: 21051275 DOI: 10.1016/j.drup.2010.10.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
5 Girard N, Cozzone D, de Leotoing L, Tournier C, Vainchtock A, Tehard B, Cortot AB. Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis. ESMO Open 2018;3:e000414. [PMID: 30233822 DOI: 10.1136/esmoopen-2018-000414] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
6 Chen J, Wang J, Zheng Q, Weng M, Wu X. Radiologic Complete Response In Lung Adenocarcinoma With Symptomatic Brain Metastasis After Systematic Therapy: A Case Study. Onco Targets Ther 2019;12:9551-7. [PMID: 31814730 DOI: 10.2147/OTT.S226735] [Reference Citation Analysis]
7 Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neuro Oncol 2015;17:488-504. [PMID: 25358508 DOI: 10.1093/neuonc/nou304] [Cited by in Crossref: 77] [Cited by in F6Publishing: 50] [Article Influence: 9.6] [Reference Citation Analysis]
8 Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int 2013;4:S265-88. [PMID: 23717798 DOI: 10.4103/2152-7806.111304] [Cited by in Crossref: 95] [Cited by in F6Publishing: 120] [Article Influence: 10.6] [Reference Citation Analysis]
9 Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 2011;8:344-56. [PMID: 21487419 DOI: 10.1038/nrclinonc.2011.58] [Cited by in Crossref: 302] [Cited by in F6Publishing: 278] [Article Influence: 27.5] [Reference Citation Analysis]
10 Bonanno L, Pavan A, Pasello G, Indraccolo S. Editorial on "The AvaALL Randomized Clinical Trial". J Thorac Dis 2019;11:S1237-40. [PMID: 31245096 DOI: 10.21037/jtd.2019.02.62] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Ferreira M, Secher T, Heuze-Vourc'H N, Reckamp KL. Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. Pharmaceutics 2021;13:912. [PMID: 34205484 DOI: 10.3390/pharmaceutics13060912] [Reference Citation Analysis]
12 Lin G, Xu H, Huang C. [Advances in treatment of brain metastases from primary non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2014;17:877-83. [PMID: 25539615 DOI: 10.3779/j.issn.1009-3419.2014.12.10] [Reference Citation Analysis]
13 Strowd RE 3rd, Knovich MA, Lesser GJ. The therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies. Curr Treat Options Oncol 2012;13:451-64. [PMID: 22829388 DOI: 10.1007/s11864-012-0207-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
14 Mortimer J, Zonder HB, Pal SK. Lessons learned from the bevacizumab experience. Cancer Control 2012;19:309-16. [PMID: 23037498 DOI: 10.1177/107327481201900407] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
15 Barresi V, Branca G, Caffo M, Caltabiano R, Ieni A, Vitarelli E, Lanzafame S, Tuccari G. Immuno-expression of endoglin and smooth muscle actin in the vessels of brain metastases. Is there a rational for anti-angiogenic therapy? Int J Mol Sci 2014;15:5663-79. [PMID: 24699047 DOI: 10.3390/ijms15045663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
16 Caffo M, Barresi V, Caruso G, Cutugno M, La Fata G, Venza M, Alafaci C, Tomasello F. Innovative therapeutic strategies in the treatment of brain metastases. Int J Mol Sci 2013;14:2135-74. [PMID: 23340652 DOI: 10.3390/ijms14012135] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
17 Qu L, Geng R, Song X. [Advances in Bevacizumab Therapy for Non-small Cell Lung Cancer 
with Brain Metastases]. Zhongguo Fei Ai Za Zhi 2016;19:515-8. [PMID: 27561800 DOI: 10.3779/j.issn.1009-3419.2016.08.05] [Reference Citation Analysis]
18 Bohn KA, Adkins CE, Nounou MI, Lockman PR. Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden. Front Pharmacol 2017;8:193. [PMID: 28443023 DOI: 10.3389/fphar.2017.00193] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
19 Monnet I, Vergnenègre A, Robinet G, Berard H, Lamy R, Falchero L, Vieillot S, Schott R, Ricordel C, Chouabe S, Thomas P, Gervais R, Madroszyk A, Abdiche S, Chiappa AM, Greillier L, Decroisette C, Auliac JB, Chouaïd C; GFPC 02-13 (METAL2) investigators. Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis. Ther Adv Med Oncol 2021;13:17588359211006983. [PMID: 33948123 DOI: 10.1177/17588359211006983] [Reference Citation Analysis]
20 Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2011;6:e22681. [PMID: 21829644 DOI: 10.1371/journal.pone.0022681] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.1] [Reference Citation Analysis]
21 Myall NJ, Yu H, Soltys SG, Wakelee HA, Pollom E. Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies. Neurooncol Adv 2021;3:v52-62. [PMID: 34859233 DOI: 10.1093/noajnl/vdab106] [Reference Citation Analysis]
22 Jubb AM, Cesario A, Ferguson M, Congedo MT, Gatter KC, Lococo F, Mulè A, Pezzella F. Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. Br J Cancer 2011;104:1877-81. [PMID: 21540863 DOI: 10.1038/bjc.2011.147] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
23 Hendriks LEL, Subramaniam DS, Dingemans AC. Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment. Front Oncol 2018;8:511. [PMID: 30460200 DOI: 10.3389/fonc.2018.00511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
24 Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-925. [PMID: 25315029 DOI: 10.1007/s40265-014-0302-9] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 15.1] [Reference Citation Analysis]
25 Leone JP, Emblem KE, Weitz M, Gelman RS, Schneider BP, Freedman RA, Younger J, Pinho MC, Sorensen AG, Gerstner ER, Harris G, Krop IE, Morganstern D, Sohl J, Hu J, Kasparian E, Winer EP, Lin NU. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res 2020;22:131. [PMID: 33256829 DOI: 10.1186/s13058-020-01372-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
26 Taylor J, Gerstner ER. Anti-angiogenic therapy in high-grade glioma (treatment and toxicity). Curr Treat Options Neurol 2013;15:328-37. [PMID: 23417315 DOI: 10.1007/s11940-013-0224-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
27 Greillier L, Tomasini P, Barlesi F. Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience. Ther Adv Respir Dis 2016;10:485-91. [PMID: 27340254 DOI: 10.1177/1753465816652083] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
28 Bai X, Zhang Y, Ding W, Wang S. Efficacy of bevacizumab in the treatment of refractory brain edema of metastatic tumors from different sources. Neurol Res 2021;43:955-60. [PMID: 34766548 DOI: 10.1080/01616412.2021.1948740] [Reference Citation Analysis]
29 Nakaya A, Kurata T, Yokoi T, Iwamoto S, Torii Y, Katashiba Y, Ogata M, Hamada M, Kon M, Nomura S. Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer. Cancer Med 2016;5:1381-7. [PMID: 27109438 DOI: 10.1002/cam4.701] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
30 Moulder SL. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials. Clin Breast Cancer 2010;10 Suppl 2:S30-40. [PMID: 20805063 DOI: 10.3816/CBC.2010.s.010] [Reference Citation Analysis]
31 Li Q, Yan H, Zhao P, Yang Y, Cao B. Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Sci Rep 2015;5:15746. [PMID: 26503902 DOI: 10.1038/srep15746] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
32 Cheng G, Zhang L. [Adverse events related to bevacizumab and the management principles in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2010;13:563-7. [PMID: 20681440 DOI: 10.3779/j.issn.1009-3419.2010.06.001] [Reference Citation Analysis]
33 Xu P, Li H. [Application of Bevacizumab in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2017;20:272-7. [PMID: 28442017 DOI: 10.3779/j.issn.1009-3419.2017.04.08] [Reference Citation Analysis]
34 Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, Anders CK, Soffietti R, Camidge DR, Vogelbaum MA, Dunn IF, Wen PY. Updates in the management of brain metastases. Neuro Oncol. 2016;18:1043-1065. [PMID: 27382120 DOI: 10.1093/neuonc/now127] [Cited by in Crossref: 118] [Cited by in F6Publishing: 99] [Article Influence: 23.6] [Reference Citation Analysis]
35 Pories SE, Wulf GM. Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. Breast Cancer (Dove Med Press) 2010;2:37-44. [PMID: 24367165 DOI: 10.2147/bctt.s6511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
36 Stefanou D, Stamatopoulou S, Sakellaropoulou A, Akakios G, Gkiaouraki M, Gkeka D, Prevezanou M, Ardavanis A. Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases. Oncol Lett 2016;12:4635-42. [PMID: 28101218 DOI: 10.3892/ol.2016.5268] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
37 Seoane J, De Mattos-Arruda L. Brain metastasis: new opportunities to tackle therapeutic resistance. Mol Oncol 2014;8:1120-31. [PMID: 24953014 DOI: 10.1016/j.molonc.2014.05.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
38 Armstrong TS, Wen PY, Gilbert MR, Schiff D. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol 2012;14:1203-14. [PMID: 22307472 DOI: 10.1093/neuonc/nor223] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
39 Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther 2012;13:247-63. [PMID: 22481432 DOI: 10.4161/cbt.19594] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
40 Lazaro T, Brastianos PK. Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. CNS Oncol 2017;6:139-51. [PMID: 28425754 DOI: 10.2217/cns-2016-0038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
41 Bachelot T, Le Rhun E, Labidi-Gally I, Heudel P, Gilabert M, Bonneterre J, Pierga JY, Gonçalves A. [Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies]. Bull Cancer 2013;100:7-14. [PMID: 23305997 DOI: 10.1684/bdc.2012.1676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
42 Ascha MS, Wang JF, Kumthekar P, Sloan AE, Kruchko C, Barnholtz-Sloan JS. Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases. Sci Rep 2019;9:17792. [PMID: 31780762 DOI: 10.1038/s41598-019-54513-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
43 Shi Y, Sun Y, Yu J, Ding C, Ma Z, Wang Z, Wang D, Wang Z, Wang M, Wang Y, Lu Y, Ai B, Feng J, Liu Y, Liu X, Liu J, Wu G, Qu B, Li X, Li E, Li W, Song Y, Chen G, Chen Z, Chen J, Yu P, Wu N, Wu M, Xiao W, Xiao J, Zhang L, Zhang Y, Zhang Y, Zhang S, Song X, Luo R, Zhou C, Zhou Z, Zhao Q, Hu C, Hu Y, Nie L, Guo Q, Chang J, Huang C, Han B, Han X, Li G, Huang Y, Shi Y. [China Experts Consensus on the Diagnosis and Treatment of Brain Metastases of Lung Cancer (2017 version)]. Zhongguo Fei Ai Za Zhi 2017;20:1-13. [PMID: 28103967 DOI: 10.3779/j.issn.1009-3419.2017.01.01] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
44 Bertolini F, Spallanzani A, Fontana A, Depenni R, Luppi G. Brain metastases: an overview. CNS Oncol 2015;4:37-46. [PMID: 25586424 DOI: 10.2217/cns.14.51] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
45 Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol. 2014;16:276. [PMID: 24353011 DOI: 10.1007/s11940-013-0276-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
46 Yoshida Y, Hoshino S, Aisu N, Naito M, Tanimura S, Sasaki T, Takeno S, Yamashita Y. Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer. Case Rep Oncol 2014;7:117-21. [PMID: 24707258 DOI: 10.1159/000360132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
47 Divine LM, Kizer NT, Hagemann AR, Pittman ME, Chen L, Powell MA, Mutch DG, Rader JS, Thaker PH. Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain. Gynecol Oncol 2016;142:76-82. [PMID: 27117923 DOI: 10.1016/j.ygyno.2016.04.030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
48 Seidel C, Hentschel B, Simon M, Schnell O, Heese O, Tatagiba M, Krex D, Reithmeier T, Kowoll A, Weller M, Wick W. A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network. J Neurol 2013;260:847-55. [PMID: 23104124 DOI: 10.1007/s00415-012-6718-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
49 Yang RF, Yu B, Zhang RQ, Wang XH, Li C, Wang P, Zhang Y, Han B, Gao XX, Zhang L, Jiang ZM. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer. Braz J Med Biol Res 2017;51:e6073. [PMID: 29185589 DOI: 10.1590/1414-431X20176073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
50 Verduin M, Zindler JD, Martinussen HM, Jansen RL, Croes S, Hendriks LE, Eekers DB, Hoeben A. Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors. Oncologist 2017;22:222-35. [PMID: 28167569 DOI: 10.1634/theoncologist.2016-0117] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
51 Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clin Transl Oncol 2012;14:564-74. [PMID: 22855137 DOI: 10.1007/s12094-012-0842-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
52 Yuan P, Gao SL. Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer. Chronic Dis Transl Med 2017;3:21-32. [PMID: 29063053 DOI: 10.1016/j.cdtm.2017.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
53 Tian Y, Zhai X, Tian H, Jing W, Zhu H, Yu J. Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases. Cancer Manag Res 2019;11:10083-92. [PMID: 31819641 DOI: 10.2147/CMAR.S222910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
54 Berghoff AS, Preusser M. Anti-angiogenic therapies in brain metastases. Memo. 2018;11:14-17. [PMID: 29606977 DOI: 10.1007/s12254-018-0384-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
55 Wang Z, Yang JJ, Tu HY, Yan HH, Wu YL. Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases. Int J Clin Oncol 2020;25:267-73. [PMID: 31587134 DOI: 10.1007/s10147-019-01552-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
56 Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, Stinchcombe TE. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e341S-e368S. [PMID: 23649446 DOI: 10.1378/chest.12-2361] [Cited by in Crossref: 121] [Cited by in F6Publishing: 116] [Article Influence: 13.4] [Reference Citation Analysis]
57 Yang L, Chen CJ, Guo XL, Wu XC, Lv BJ, Wang HL, Guo Z, Zhao XY. Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis. J Neurooncol 2018;137:49-56. [PMID: 29170906 DOI: 10.1007/s11060-017-2693-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
58 Kim YH, Nagai H, Ozasa H, Sakamori Y, Mishima M. Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review). Biomed Rep 2013;1:691-6. [PMID: 24649011 DOI: 10.3892/br.2013.151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
59 Bohn JP, Pall G, Stockhammer G, Steurer M. Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors. Target Oncol 2016;11:263-75. [PMID: 26822319 DOI: 10.1007/s11523-015-0414-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
60 Yamamoto D, Iwase S, Tsubota Y, Sueoka N, Yamamoto C, Kitamura K, Odagiri H, Nagumo Y. Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial. Onco Targets Ther 2012;5:185-9. [PMID: 23049262 DOI: 10.2147/OTT.S36515] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
61 Freedman RA, Anders CK. Treatment of Breast Cancer Brain Metastases. Curr Breast Cancer Rep 2012;4:1-9. [PMID: 22754605 DOI: 10.1007/s12609-011-0061-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
62 Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar CT, Huang Y, Ager E, Kamoun W, Goel S, Snuderl M, Lussiez A, Hiddingh L, Mahmood S, Tannous BA, Eichler AF, Fukumura D, Engelman JA, Jain RK. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U S A 2012;109:E3119-27. [PMID: 23071298 DOI: 10.1073/pnas.1216078109] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 10.3] [Reference Citation Analysis]
63 Russo AE, Priolo D, Antonelli G, Libra M, McCubrey JA, Ferraù F. Bevacizumab in the treatment of NSCLC: patient selection and perspectives. Lung Cancer (Auckl) 2017;8:259-69. [PMID: 29276417 DOI: 10.2147/LCTT.S110306] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
64 Nishimura T, Furihata M, Kubo H, Tani M, Agawa S, Setoyama R, Toyoda T. Intracranial hemorrhage in patients treated with bevacizumab: Report of two cases. World J Gastroenterol 2011; 17(39): 4440-4444 [PMID: 22110272 DOI: 10.3748/wjg.v17.i39.4440] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
65 De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010;100:443-7. [PMID: 20440540 DOI: 10.1007/s11060-010-0200-2] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
66 Lin NU. Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience 2013;7:307. [PMID: 23662165 DOI: 10.3332/ecancer.2013.307] [Cited by in Crossref: 4] [Cited by in F6Publishing: 26] [Article Influence: 0.4] [Reference Citation Analysis]
67 Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther 2012;13:247-63. [PMID: 22481432 DOI: 10.4161/cbt.19594] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Goldlust SA, Graber JJ, Bossert DF, Avila EK. Headache in patients with cancer. Curr Pain Headache Rep 2010;14:455-64. [PMID: 20927609 DOI: 10.1007/s11916-010-0153-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
69 Sankey EW, Tsvankin V, Grabowski MM, Nayar G, Batich KA, Risman A, Champion CD, Salama AKS, Goodwin CR, Fecci PE. Operative and peri-operative considerations in the management of brain metastasis. Cancer Med 2019;8:6809-31. [PMID: 31568689 DOI: 10.1002/cam4.2577] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
70 Chinese Society of Clinical Oncology, Expert Committee on Vessel Targeted Therapy, Expert Committee on Non-small Cell Lung Cancer, Expert Group on Antiangiogenic Drugs for Non-small Cell Lung Cancer. [Chinese Expert Consensus on Antiangiogenic Drugs for Advanced Non-small Cell Lung Cancer (2019 Edition)]. Zhongguo Fei Ai Za Zhi 2019;22:401-12. [PMID: 31315778 DOI: 10.3779/j.issn.1009-3419.2019.07.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Hirai F, Seto T, Inamasu E, Shimokawa M, Toyokawa G, Yoshida T, Nosaki K, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y. Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer. Oncol Lett 2015;9:2577-82. [PMID: 26137109 DOI: 10.3892/ol.2015.3086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
72 Lunacsek OE, Ravelo A, Coutinho AD, Hazard SJ, Green MR, Willey J, Eaddy M, Goertz HP. First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices. Drugs Real World Outcomes 2016;3:333-43. [PMID: 27747837 DOI: 10.1007/s40801-016-0090-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
73 Finkelmeier F, You SJ, Waidmann O, Wolff R, Zeuzem S, Bähr O, Trojan J. Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. J Gastrointest Cancer 2016;47:82-8. [PMID: 26714801 DOI: 10.1007/s12029-015-9795-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
74 Danciu OC, Rayani S, Michals EA, Villano JL. Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases. Med Oncol 2012;29:2619-22. [PMID: 22209841 DOI: 10.1007/s12032-011-0148-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]